Cone rod dystrophy is a rare inherited retinal disorder impacting cones and rods, leading to progressive vision loss. The market for cone rod dystrophy is poised for growth due to rising disease ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Unfortunately, I have been diagnosed many years back with Retinal Dystrophy ( genetic mutation ). The condition has no ...

Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal ...

Opus Genetics (IRD) announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical trial for Best disease. Best disease, or vitelliform macular dystrophy, is a rare ...

Effective management of inherited retinal diseases requires a comprehensive approach to diagnosis and treatment, according to ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

To date in the Phase 1/2 portion of the trial, six late-stage participants have been treated with OPGx-LCA5, and all six have experienced clinically meaningful improvements in vision, providing ...

1 Department of Ophthalmology, Jinan Second People’s Hospital, Jinan, China 2 Nova Southeastern University College of Optometry, Miami, FL, United States Purpose: This study aimed to evaluate the ...

"The ISPE Annual Meeting is an important event in pharmaceutical engineering, regulatory compliance, and supply chain innovation, and I'm excited to exchange ideas and learn from colleagues across the ...